Additive effects of leflunomide and tacrolimus in prevention of islet xenograft rejection

Scandinavian Journal of Immunology

Volumn 59, Issue 3, 2004, Pages 255-260

  Zhang, L ^a   Qi, Z ^b   Wu, D ^a   Shan, S ^a   Ekberg, H ^b  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HYPNORM; LEFLUNOMIDE; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; DRUG POTENTIATION; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CAPSULE; MALE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; SURVIVAL TIME; T LYMPHOCYTE SUBPOPULATION; XENOGRAFT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG SYNERGISM; GRAFT REJECTION; HISTOCYTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; ISLETS OF LANGERHANS TRANSPLANTATION; ISOXAZOLES; LYMPHOCYTE SUBSETS; MALE; MICE; MICE, INBRED BALB C; RATS; RATS, WISTAR; T-LYMPHOCYTES; TACROLIMUS; TRANSPLANTATION, HETEROLOGOUS;

EID: 1842452888     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2004.01401.x     Document Type: Article

References (30)

1. Hirano Y, Fujihira S, Ohara K et al. Morphological and functional changes of islets of Langerhans in FK506-treated rats. Transplantation 1992;53:889-94.
2. Jindal RM. Posttransplant diabetes mellitus - a review. Transplantation 1994;58:1289-98.
3. Drachenberg CB, Klassen DK, Weir MR et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999;68:396-402.
4. Mladenovic V, Domljan Z, Rozman B et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995;38:1595-603.
5. D'Silva M, Candinas D, Achilleos O et al. The immunomodulatory effect of leflunomide in rat cardiac allotransplantation. Transplantation 1995;60:430-7.
6. McChesney LP, Xiao F, Sankary HN et al. An evaluation of leflunomide in the canine renal transplantation model. Transplantation 1994;57:1717-22.
7. Williams JW, Xiao F, Foster P et al. Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. Transplantation 1994;57:1223-31.
8. Schorlemmer HU, Bartlett RR, Schleyerbach R. Effect of leflunomide and cyclosporine on graft survival and changes in lymphocyte phenotypes in a rat heart allotransplantation model. Transpl Immunol 1998;6:48-52.
9. Morris RE, Huang X, Cao W et al. Leflunomide (HWA 486) and its analog suppress T-and B-cell proliferation in vitro, acute rejection, ongoing rejection, and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey transplant recipients as well as arterial intimal thickening after balloon catheter injury. Transplant Proc 1995;27:445-7.
10. Östraat Ö, Qi Z, Tufveson G et al. The effects of leflunomide and cyclosporin A on rejection of cardiac allograft in rat. Scand J Immunol 1998;47:236-42.
11. Vriens PW, Pollard JD, Hoyt G et al. Hamster cardiac xenografts are protected against antibody mediated damage, early after transplantation to Lewis rats. Xenotransplantation 2001;8:239-46.
12. Wennberg L, Song Z, Bennet W et al. Diabetic rats transplanted with adult porcine islets and immunosuppressed with cyclosporine A, mycophenolate mofetil, and leflunomide remain normoglycemic for up to 100 days. Transplantation 2001;71:1024-33.
13. Bartlett RR, Dimitrijevic M, Mattar T et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 1991;32:10-21.
14. Xu X, Williams JW, Bremer EG et al. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995;270:12398-403.
15. Qi Z & Ekberg H. Malononitrilamides 715 and 279 prolong rat cardiac allograft survival, reverse ongoing rejection, inhibit allospecific antibody production and interact positively with cyclosporin. Scand J Immunol 1998;48:379-88.
16. Qi Z, Simanaitis M, Ekberg H. Malononitrilamides 715 and 279 prevent accelerated cardiac allograft rejection synergistically with cyclosporin A in presensitized rats. Transpl Immunol 1998;6: 94-100.
17. Qi Z, Simanaitis M, Ekberg H. Malononitrilamides and tacrolimus additively prevent acute rejection in rat cardiac allografts. Transpl Immunol 1999;7:169-75.
18. Rastellini C, Cicalese L, Leach R et al. Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide. Transplant Proc 1999;31:646-7.
19. Lacy PE & Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 1967;16:35-9.
20. Scharp DW, Kemp CB, Knight MJ et al. The use of ficoll in the preparation of viable islets of langerhans from the rat pancreas. Transplantation 1973;16:686-9.
21. Smith RM & Mandel TE. Pancreatic islet xenotransplantation: the potential for tolerance induction. Immunol Today 2000;21:42-8.
22. Grimes HL, Kaufman CL, Rivoli R, Ildstad ST. Graft tolerance and acceptance in xenotransplantation. Curr Opin Org Transplant 2002;7:46-50.
23. Ericzon BG, Wijnen RM, Kubota K et al. FK506-induced impairment of glucose metabolism in the primate - studies in pancreatic transplant recipients and in nontransplanted animals. Transplantation 1992;54:615-20.
24. Silva Junior HT & Morris RE. Leflunomide and malononitrilamides. Am J Med Sci 1997;313:289-301.
25. Chong AS, Rezai K, Gebel HM et al. Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro. Transplantation 1996;61:140-5.
26. Cherwinski HM, McCarley D, Schatzman R et al. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J Pharmacol Exp Ther 1995; 272:460-8.
27. Lang R, Wagner H, Heeg K. Differential effects of the immunosuppressive agents cyclosporine and leflunomide in vivo. Leflunomide blocks clonal T cell expansion yet allows production of lymphokines and manifestation of T cell-mediated shock. Transplantation 1995;59:382-9.
28. Wilson JD, Simeonovic CJ, Ting JHL et al. Role of CD4+ T-lymphocytesin rejection by mice of fetal pig proislet xenografts. Diabetes 1989;38:217-9.
29. Friedman T, Smith RN, Colvin RB et al. A critical role for human CD4+ T-cells in rejection of porcine islet cell xenografts. Diabetes 1999;48:2340-8.
30. Guo Z, Chong AS, Shen J et al. In vivo effects of leflunomide on normal pancreatic islet and syngeneic islet graft function. Transplantation 1997;63:716-21.